Amifostine (Ethyol) to Reduce Mucositis, Decrease Haematological Toxicities, and Improve Salivary Sparing in Patients with Locally Advanced Head and Neck Cancer Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy (IMRT): A Phase II Study

Trial Profile

Amifostine (Ethyol) to Reduce Mucositis, Decrease Haematological Toxicities, and Improve Salivary Sparing in Patients with Locally Advanced Head and Neck Cancer Treated with Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy (IMRT): A Phase II Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2013

At a glance

  • Drugs Amifostine (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top